MT7117 Study - Wesley Research Institute
Wesley Research Institute

This study is testing a potential new treatment for EPP or XLP that increases melanin in the skin, which protects you from sunlight.

Research Objectives





Study location

Wesley Research Institute

Study type

Industry Sponsored

Patient group

Indication: Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP)

Industry sponsor

Mitsubishi Tanabe Pharma Development

About this clinical trial

Erythropoietic Protoporphyria (referred to as “EPP”) or X-Linked Protoporphyria (referred to as “XLP”) are characterized by the accumulation of a molecule named protoporphyrin in the body, which leads to pain when the skin is exposed to sunlight. The purpose of this trial is to investigate whether an experimental drug called MT-7117 (Dersimelagon) is effective and well tolerated in reducing the severity of symptoms of EPP or XLP.

Lead investigator

  • Prof David Coman

Clinical trial coordinator

  • Venita Bali

Technical title

A Phase 3, Multicenter, Open-Label, Long-term, Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (MT-7117) in Subjects with Erythropoietic Protoporphyria (EPP) or X-linked Protoporphyria (XLP)

This clinical trial is now closed for recruitment

If you would like more information about this trial, please complete the contact form below.

Would you like to be updated on the progress of our research?(Required)
By submitting this form you consent for us to hold your information in accordance with our Privacy Policy
I consent to receive updates on Wesley Research Institute news and events, clinical trials, research projects and how to support WRI.
This field is for validation purposes and should be left unchanged.
linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram